Published in final edited form as:

Int J Gynaecol Obstet. 2016 May ; 133(2): 217–220. doi:10.1016/j.ijgo.2015.08.025.

Progestin-based contraceptive on the same day as medical abortion

Jeanna Park^{a,*}, Nuriya Robinson^a, Ursula Wessels^b, James Turner^b, and Stacie Geller^{a,c}

^aDepartment of Obstetrics and Gynecology, University of Illinois, Chicago, USA

^bDepartment of Obstetrics and Gynecology, Lower Umfolozi District War Memorial Hospital, Empangeni, South Africa

^cDepartment of Obstetrics and Gynecology, Center for Research on Women and Gender, Chicago, USA

Abstract

Objective—To determine the success rate of medical abortion when a progestin-based contraceptive—either an etonogestrel implant or depot medroxyprogesterone acetate (DMPA) injection—is given on the same day as mifepristone for medical abortion.

Methods—In a retrospective chart review, data were assessed for women aged 15–49 years who underwent medical abortion (63 days of pregnancy) at two hospitals in KwaZulu Natal, South Africa, between August 2013 and July 2014. The women were given oral mifepristone (200 mg) and buccal misoprostol (800 µg), and received an etonogestrel implant or DMPA injection on the same day as mifepristone. The primary outcome was the success rate of medical abortion. Comparative data were obtained through a PubMed search.

Results—A total of 89 women were included. Complete termination was achieved in 87 (98%, 95% confidence interval 95%–100%) women. This success rate is similar to that reported in a previous systematic review of the rate of medical abortion success without progestin contraceptive administration (94.8%).

Conclusions—Administration of a progestin-based contraceptive such as an etonogestrel implant or DMPA injection on the same day as mifepristone for medical abortion did not alter the success rates.

Keywords

Depot medroxyprogesterone acetate; Etonogestrel; Medical abortion

*Corresponding author at: Department of Obstetrics and Gynecology, University of Illinois, Chicago, 820 South Wood Street, M/C 808, Chicago, IL 60612, USA. Tel.: +1 312 996 7430, +1 415 680 4393; fax: +1 312 996 4238. ; Email: jeanna.park@gmail.com (J. Park)

Conflict of interest

The authors have no conflicts of interest.

1. Introduction

In South Africa, the maternal mortality rate is estimated to be 300 per 100 000 live births [¹]. Although this country boasts a health infrastructure that is superior to many other Sub-Saharan African countries, the maternal mortality rate has quadrupled in the past decade [²]. The Choice on Termination of Pregnancy Act of 1996 legalized induced abortion for fetuses of up to 12 gestational weeks at the request of the woman, and up to 20 gestational weeks if the pregnancy would adversely affect the woman's mental, physical, social, or economic status, or if it resulted from rape or incest [³]. Despite this liberal legislature, unsafe abortion continues to be one of the top five leading causes of maternal death in South Africa.

Medical abortion with mifepristone and misoprostol was approved by the Medicines Control Council of South Africa in 2001 [⁴]. Since then, medical abortion has been offered in this country, generally with a second follow-up appointment that confirms complete passage of the products of conception and provides contraceptive counseling. This two-visit protocol is similar to that in the USA and other countries; however, in resource-limited settings such as rural South Africa, follow-up rates are often low and maternal complications from a future undesired pregnancy are extremely high. Although exact statistics are unknown, the follow-up after medical and surgical abortion in this region is generally less than 30% (oral communication, district health specialist in KwaZulu Natal, 2015). Furthermore, abortion complications from undesired pregnancies are exceedingly high in South Africa, irrespective of a history of abortion. It is estimated that more than 100 000 women are hospitalized annually in South Africa for abortion complications [⁵]. In such settings where contraception is of paramount importance, a one-visit approach with contraceptive administration on the same day as medical abortion should be considered to decrease the rate of unintended pregnancy.

KwaZulu Natal—the second most populous province in South Africa—has the highest proportion of maternal deaths, accounting for 22% of pregnancy- and childbirth-related deaths nationwide [³]. In this province, the third leading cause of maternal mortality when non-pregnancy-related infections are excluded (i.e. HIV/AIDS) is complications after unsafe termination of pregnancy, and the maternal mortality rate attributable to this often preventable cause of death has risen by 85% in the past 5 years [³]. These statistics underscore the importance of preventing unplanned and unwanted pregnancies. The KwaZulu Natal Department of Health has responded by intensifying family planning and contraception services. One strategy currently in place to decrease the rate of unintended pregnancies is the insertion of an etonogestrel subdermal implant (Implanon; Merck, Kenilworth, NJ, USA) or injection of depot medroxyprogesterone acetate (DMPA) contraceptive at the same time as mifepristone administration for medical abortion.

This one-visit strategy has obvious potential benefits; however, there is a theoretical concern that providing a progestin-based contraceptive (i.e. etonogestrel or DMPA) on the same day as mifepristone might interfere with the anti-progestin effects of mifepristone, resulting in an incomplete abortion or ongoing pregnancy. Historically, the rates of medical abortion completion using the same mifepristone and misoprostol regimen as used in South Africa (200 mg oral mifepristone, followed by 800 µg of sublingual misoprostol 24–48 hours later)

is high (nearly 95%) [6]. Nevertheless, few data are available regarding the success rate of the medical abortion regimen when progestin contraceptives are administered on the same day as mifepristone [7–9].

Pharmacokinetic studies of mifepristone show that it is present in the blood within 1–2 hours of administration [10]. Etonogestrel levels sufficient to prevent ovulation can be detected within 8 hours of subdermal implant administration [8]. DMPA can also be detected as early as 20 minutes after intramuscular injection, with levels steadily peaking to effective concentrations within 24 hours [11]. In the USA, because mifepristone is a competitive inhibitor of progesterone receptors, contraception is usually initiated after documented completion of medical abortion at a follow-up visit to minimize potential abortion failure. However, even in high-income countries such as the USA, follow-up rates for medical abortion can be as low as 50% [7]. Thus, effective contraception (including progestin-based contraceptives) on the same day of medical abortion is currently being provided in some KwaZulu Natal facilities, as advised by WHO [12].

The aim of the present study was to determine the success rate of medical abortion, defined as complete passage of products of conception, at up to 63 days of pregnancy when a progestin-based contraceptive, namely an etonogestrel implant or DMPA injection, is given on the same day as mifepristone.

2. Materials and methods

In the present retrospective chart review, data were obtained for women who underwent medical abortion at two hospitals in rural KwaZulu Natal, South Africa (Lower Umfolozi District War Memorial Hospital and Eshowe Hospital) between August 1, 2013, and July 21, 2014. The period chosen reflected both the first year that the etonogestrel implant was available in KwaZulu Natal and the beginning of the same-day contraceptive initiative in this region. The medical records of women who met the inclusion criteria were eligible for the study: aged 15–49 years, elective medical termination of pregnancy with mifepristone and misoprostol, gestational age of the fetus of 63 days or less as determined by ultrasonography, receipt of either an etonogestrel implant or DMPA injection for contraception on the same day as mifepristone, and follow-up in the clinic or by phone. Charts were excluded from the study if women presented at more than 63 days of pregnancy, did not follow the study site's standard medical abortion regimen, elected for surgical abortion, did not receive contraception on the same day as mifepristone, or failed to complete follow-up.

The Institutional Review Board of University of Illinois (Chicago, IL, USA) and the Ethics Committee of Human Sciences Research Council in South Africa approved the study before it began. Informed consent was waived given the retrospective nature of the study and its status of minimal risk research without patient recruitment or contact.

All women in the study who underwent medical abortion followed the standard medical abortion protocol at each study site with 200 mg of oral mifepristone taken in the clinic, followed by 800 µg of sublingual misoprostol taken 24–48 hours later at home. The chosen

method of contraception—either etonogestrel implant or DMPA injection—was administered immediately after mifepristone consumption. Women were instructed to attend follow-up 10–14 days later, at which time completion of pregnancy termination was determined by history and physical examination followed by ultrasonography if clinically suspicious for incomplete abortion (at Lower Umfolozi District War Memorial Hospital), or by ultrasonography alone (at Eshowe Hospital).

Medical abortion failure was defined as retained products of conception requiring subsequent surgical evacuation. If a woman did not return to the clinic for follow-up, a brief phone interview was conducted to verify completion of medical abortion by history alone. Phone follow-up was performed by a technique similar to previously described methods [13, 14]. During the phone interview, the woman was asked a set of standardized questions, including if and how she used the misoprostol, if she had heavy bleeding and/or passed clots or tissue after misoprostol use, if she continued to have bleeding or pregnancy symptoms (i.e. breast tenderness or nausea), and if she believed she had passed the products of conception. If the interviewer believed that she had completely passed the pregnancy on the basis of her answers, a note documenting medical abortion completion was recorded in the chart. If there was a suspicion of ongoing pregnancy, the woman was asked to return for ultrasonography.

The principal investigator (J.P.) was responsible for extracting the data and performing the chart review. Eligible patients were identified from the medical abortion log books at each study site. The corresponding medical charts were then located and obtained from the medical records department at the respective facilities. After each chart was given a unique identifier number, a data collection form was completed by hand for each chart with the corresponding identifier. The completed data collection forms were entered into an Excel database (Microsoft Corporation, Redmond, WA, USA) for analysis.

To provide comparative data, a PubMed search with the terms “medical abortion,” “misoprostol,” and “mifepristone” was performed to identify systematic reviews demonstrating the success rates of medical abortion at 9 weeks of pregnancy or less previously published in English or as an English translation. The results were narrowed down to trials using the identical route, dosage, and timing of misoprostol and mifepristone used in the present chart review.

The primary outcome was the success rate of medical abortion when the etonogestrel implant or DMPA for contraception was given on the same day as mifepristone. Women’s previous methods of contraception, and contraception chosen at the time of medical abortion were also examined.

The data were analyzed by descriptive statistics using Microsoft Excel. SPSS version 20.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Independent sample *t* tests and χ^2 tests were used to determine whether there was a significant relationship between demographic variables and the primary outcome. *P* 0.05 was taken to be statistically significant.

3. Results

A total of 89 women were included in the retrospective chart review. Table 1 shows their characteristics. The women in the study were aged between 17 and 42 years. Women presented with a mean pregnancy length of 53 ± 8 days, and all women presented at a maximum of 63 days. Among the 77 women with known HIV status, 27 (35%) were HIV-positive.

Among the 89 women receiving an etonogestrel implant or DMPA injection on the same day as mifepristone, 87 (98%, 95% confidence interval 95%–100%) had a complete termination, and 2 (2%) required surgical evacuation for an incomplete abortion (Table 2). A PubMed search indicated that this success rate was similar to that reported in a systematic review of the rate of medical abortion success without progestin contraceptive administration (94.8%) [6]. Both the failures were in women with a gravidity of 1, one at 28 days and one at 62 days of pregnancy. Both women had received DMPA for contraception on the day of mifepristone administration.

Demographic variables including patient age, gestational age, and parity were not significantly related to previous method of contraception, chosen contraception at time of medical abortion, or medical abortion success (data not shown).

In terms of contraceptive choices, approximately half the study women had not used any contraception in the previous year (Table 1). Of those who stated using contraception in the past year, most reported using DMPA. In addition, more women chose DMPA than etonogestrel implant at time of medical abortion: 51 (57%) versus 38 (43%).

4. Discussion

The present study adds to the growing—yet still scarce—data on the success rate of medical abortion when a progestin-based contraceptive implant or injection is administered on the first day of medical abortion. Among the 89 study women, the completion of medical abortion was 98%. This was found to be similar to historical rates reported in a systematic review of previous studies using the same mifepristone and misoprostol dose and route of administration for medical abortion without contraception administration at 63 days of pregnancy or less [6]. Although a true comparison with previous studies cannot be made given the probable differences in patient population, the low failure rate in the present study indicates that administering an etonogestrel implant or DMPA on the first day of medical abortion does not alter the effects of mifepristone.

A small pilot trial of 20 patients attending a clinic at Boston University assessed patient satisfaction regarding insertion of an etonogestrel implant at time of mifepristone for medical abortion [7]. Overall, 19 attended follow-up and reported completion of the medical abortion, although the study was not powered to determine a significant difference in failure rates. A second pilot study by the same authors assessed similar factors when DMPA was administered at time of medical abortion for 20 patients [9]. Three treatment failures were recorded in this cohort and, notably, the follow-up data demonstrated poor continuation rates for the DMPA injection (15.7%). Another pilot trial among 39 patients in the UK [8]

attempted to assess the success rates of medical abortion when the etonogestrel implant was inserted on the day of mifepristone; however, this trial was not powered sufficiently to demonstrate a statistically significant difference in efficacy nor did it include DMPA.

The present study has some limitations, including its retrospective nature, lack of comparison group (apart from historical data), and scant demographic data. Furthermore, it was not possible to compare the present cohort with the entire population of women who received a medical abortion with same-day contraception because this information was incomplete in the medical records as a result of lack of follow-up by some patients. Nevertheless, a compelling benefit of using a single-visit approach to medical abortion included an increased uptake of contraception among women seeking abortions in the two study clinics. Given that nearly half the women were not using contraception in the past year, but all opted to receive contraception with their medical abortion, same-day initiation probably improved access to contraception. This effect could result from a combination of patients receiving contraception who otherwise would have been lost to follow-up, and patients who were able to receive coordinated and mandatory contraceptive counseling using the one-visit protocol in the two clinics.

In conclusion, providing a progestin-based contraceptive via an etonogestrel implant or DMPA injection on the same day as mifepristone did not affect the success rate of medical abortion. Clearly, further prospective studies are needed to assess the success rates with concurrent placement of progestin-based contraceptives in a randomized manner to control for variables that the present study might not have included (e.g. weight and smoking, among others). In addition, larger acceptability and satisfaction studies to determine continuation or discontinuation of the chosen contraceptive, bleeding or adverse effect profiles, and time to next pregnancy are necessary. Nevertheless, a streamlined one-visit approach for medical abortion and contraceptive placement on the same day might be an acceptable option, especially in lower-resource settings with low follow-up rates.

Acknowledgments

The study was funded by the Global Women's Health Fellowship at the University of Illinois, Chicago, IL, USA.

References

1. World Health Organization. [Accessed April 20, 2015] Maternal Mortality. Fact Sheet No. 348. <http://www.who.int/mediacentre/factsheets/fs348/en/>. Published 2012
2. Human Rights Watch. [Accessed April 20, 2015] World Report 2011: South Africa. <https://www.hrw.org/video-photos/interactive/2012/01/19/world-report-2012>. Published 2011
3. South Africa: Department of Health; Saving Mothers 2011–2013: Sixth report on the confidential enquiries into maternal deaths in South Africa. <http://www.kznhealth.gov.za/mcwh/Maternal/Saving-Mothers-2011-2013-short-report.pdf>. Published 2015 [Accessed April 20, 2015]
4. Kawonga M, Blanchard K, Cooper D, Cullingworth L, Dickson K, Harrison T, et al. Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa. *J Fam Plann Reprod Health Care*. 2008; 34(3):159–164. [PubMed: 18577314]
5. Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. *Lancet*. 2006; 368(9550):1887–1892. [PubMed: 17126721]

6. Raymond EG, Shannon C, Weaver MA, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. *Contraception*. 2013; 87(1):26–37. [PubMed: 22898359]
7. Sonalkar S, Hou MY, Borgatta L. Administration of the etonogestrel contraceptive implant on the day of mifepristone for medical abortion: a pilot study. *Contraception*. 2013; 88(5):671–673. [PubMed: 24028749]
8. Church E, Sengupta S, Chia KV. The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy. *Sex Reprod Health*. 2010; 1(3):105–109.
9. Sonalkar S, McClusky J, Hou MY, Borgatta L. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study. *Contraception*. 2015; 91(2): 174–177. [PubMed: 25481376]
10. Spitz IM, Bardin CW. Clinical pharmacology of RU 486—an antiprogesterin and antigluocorticoid. *Contraception*. 1993; 48(5):403–404. [PubMed: 8275693]
11. Schreiber, C.; Barnhart, K. Contraception. In: Strauss, J.; Barbieri, R., editors. *Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management*. Philadelphia: Elsevier Saunders; 2014. p. 903
12. World Health Organization. [Accessed April 20, 2015] Safe abortion: technical and policy guidance for health systems. Second http://apps.who.int/iris/bitstream/10665/70914/1/9789241548434_eng.pdf?ua=1. Published 2012
13. Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. *Contraception*. 2004; 70(4):313–317. [PubMed: 15451336]
14. Perriera LK, Reeves MF, Chen BA, Hohmann HL, Hayes J, Creinin MD. Feasibility of telephone follow-up after medical abortion. *Contraception*. 2010; 81(2):143–149. [PubMed: 20103453]

Table 1Demographic and reproductive characteristics of the study women.^a

Characteristic	Value (n = 89)
Age, y	24.8 ± 5.3
Parity	
0	22 (25)
1	34 (38)
2	15 (17)
3	11 (12)
Missing data	7 (8)
Length of pregnancy, d	
49	31 (35)
50–56	33 (37)
57–63	22 (25)
Missing data	3 (3)
HIV status	
Negative	50 (56)
Positive	27 (30)
Missing data	12 (14)
Contraception in past year	
None	44 (49)
Condoms	1 (1)
Oral contraceptive pills	1 (1)
Depot medroxyprogesterone acetate injection	36 (40)
Missing data	7 (8)

^aValues are given as mean ± SD or number (percentage).

Table 2Chosen contraceptive by completion of medical abortion.^a

Contraception at time of abortion	Complete abortions	Incomplete abortion
Etonogestrel implant (n = 38)	38 (100)	0
Depot medroxyprogesterone acetate injection (n = 51)	49 (96)	2 (4)
Total (n = 89)	87 (98)	2 (2)

^aValues are given as number (percentage).